-
Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study
24 Apr 2024 23:09 GMT
… in a condition of androgen and estrogen deprivation. However, since sex hormones … agonists are FSH levels during therapy, which are mildly higher with …
-
Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside.
23 Apr 2024 11:53 GMT
… sequentially combined under concurrent androgen deprivation for treating locally advanced PC … treated with the combination therapy showed significantly improved outcomes regarding … curative potential of the combination therapy.
Theranostics. 2024 Apr 08*** …
-
Astellas announces EC approval of Xtandi for expanded prostate cancer use
25 Apr 2024 11:38 GMT
… announced that its Pfizer-partnered androgen receptor signalling inhibitor Xtandi (enzalutamide … monotherapy or in combination with androgen deprivation therapy (ADT) in adults with high … prostate cancer, the first hormone therapy available in the EU to …
-
A Randomized Trial Comparing Quality of Life after LDR or HDR Prostate Brachytherapy Boost with Pelvic External Beam Radiation Therapy - Beyond the Abstract
22 Apr 2024 20:25 GMT
… VMAT technique (volumetric modulated arc).
Androgen deprivation (ADT) was used in 74% … with Pelvic External Beam Radiation Therapy. Int J Radiat Oncol Biol … . Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the …
-
Salvage Reirradiation for Locally Recurrent Prostate Cancer: Results From a Prospective Study With 7.2 Years of Follow-Up.
25 Apr 2024 07:49 GMT
… recurrence after primary curative radiation therapy for prostate cancer (PCa), as … volume and 6 months of androgen-deprivation therapy starting 3 months before radiation … PCa after primary curative radiation therapy is clinically feasible and demonstrated …
-
Patient Preference of Apalutamide Versus Enzalutamide for Recurrent or Metastatic Hormone-sensitive Prostate Cancer: An Open-label, Randomized, Crossover Trial.
25 Apr 2024 07:49 GMT
… high-volume and on continued androgen deprivation therapy were recruited. All subjects received …
-
EC grants label extension approval for Astellas' Xtandi for use in additional recurrent early prostate cancer treatment setting
25 Apr 2024 06:20 GMT
… monotherapy or in combination with androgen deprivation therapy (ADT) for the … radiotherapy; in combination with androgen deprivation therapy for the treatment of adult … symptomatic after failure of androgen deprivation therapy in whom chemotherapy is …
-
The Critical Interplay of CAF Plasticity and Resistance in Prostate Cancer.
24 Apr 2024 14:58 GMT
… driven by the androgen receptor (AR) pathway, with androgen deprivation therapy (ADT) being a … also underscores the association between therapy-induced phenotypic alterations of CAFs …
-
European Commission approves Astellas’ drug for expanded prostate cancer Treatment
24 Apr 2024 14:24 GMT
… monotherapy or in combination with androgen deprivation therapy (ADT) for adult men with …
-
EC approves Astellas’ Xtandi for high-risk prostate cancer treatment
24 Apr 2024 11:23 GMT
… monotherapy or in combination with androgen deprivation therapy for treating adult men with … first and only novel hormone therapy for this patient group in …